Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Fidelity

Fidelity Disruptive Medicine ETF (FMED)

Ticker FMED · · Holdings as of May 31, 2026

Expense ratio
0.5%$50/yr per $10k
5-yr return
−0.2%annualized
1-yr return
+9.7%as of Sep 2026
Net assets
$41.0Mall share classes
Holdings
70

Bottom line

Is FMED a good fund? The bottom line

FMED is an actively managed large blend ETF from Fidelity.

Annual fees run 0.5% — about $50 a year on every $10,000 invested, cheaper than 77% of large blend funds we track.

It returned +9.7% over one year, −0.2% a year over five years (as of Sep 30, 2026, per its prospectus).

With $41.0 million in net assets and 70 holdings, its largest position is Fidelity Revere Street Trust (10.3%) and the top 10 make up 39.4% of the portfolio.

What stands out

  • Low cost: cheaper than 77% of large blend peers

What to watch

  • 5-year return in the bottom quarter of its category
  • Small fund ($41.0 million) — small funds are likelier to close

Updated Nov 19, 2026

What FMED invests in

Fidelity Disruptive Medicine ETF seeks long-term growth of capital.

"Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Disruptive medicine companies are companies that have or are developing innovative ways of doing business that may be disruptive in the development, design, manufacture, or distribution of products, processes, or services in the medical field. Companies within the disruptive medicine theme include but are not limited to those companies that, in…

From the fund's prospectus (filed Sep 24, 2026).

FMED performance

Fund calendar-year total returns, 2021–2025 2021: +11.0%; 2022: −21.7%; 2023: +1.4%; 2024: +2.5%; 2025: +9.7% +11.0% 2021 −21.7% 2022 +1.4% 2023 +2.5% 2024 +9.7% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
FMED+9.7%−0.2%—
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Sep 30, 2026

Full FMED performance history →

What FMED costs

On a $10,000 investment, FMED's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full FMED fee table →

FMED top 10 holdings

#Holding% of fund
1Fidelity Revere Street Trust10.27%
2Ucb Sa4.73%
3Lifestance Health Group Inc4.27%
4Danaher Corp3.42%
510x Genomics Inc3.11%
6Intuitive Surgical Inc2.92%
7Cogent Biosciences Inc2.85%
8Alnylam Pharmaceuticals Inc2.79%
9Argenx Se2.78%
10Legend Biotech Corp2.29%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 39.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to FMED

More funds like FMED →

FMED FAQ

What is the expense ratio of FMED?
FMED's expense ratio is 0.5%, which works out to about $50 a year for every $10,000 invested. The prospectus estimates total costs of $628 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is FMED a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 77% of large blend peers; 5-year return in the bottom quarter of its category; small fund ($41.0 million) — small funds are likelier to close. This is general information, not personalized advice.
What does FMED hold?
FMED's largest holdings are Fidelity Revere Street Trust (10.3%), Ucb Sa (4.7%), Lifestance Health Group Inc (4.3%), Danaher Corp (3.4%), 10x Genomics Inc (3.1%). It holds 70 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is FMED's 5-year return?
FMED returned −0.2% a year over the five years ending Sep 30, 2026. Past performance does not guarantee future results.
Who manages FMED?
FMED is offered by Fidelity through Fidelity Covington Trust.